Investing.com -- A Meta Platforms (NASDAQ: META) research scientist has delivered a harsh critique of the company’s ...

Investing.com -- Nurix Therapeutics Inc (NASDAQ: NRIX) reported better-than-expected financial results for its fiscal second quarter ended May 31, 2025, driven by significant milestone payments from ...

Investing.com -- Ultragenyx Pharmaceutical (TADAWUL: 2070) Inc. (NASDAQ: RARE) stock plummeted 33% after the company announced its Phase 3 Orbit study for UX143 (setrusumab) in osteogenesis imperfecta ...